$3.34
▲ +$0.22
(+7.05%)
Vol 2.7M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$376.7M
ROE
-54.8%
Margin
-419575.0%
D/E
7.78
Beta
0.01
52W
$3–$8
Wall Street Consensus
15 analysts · Apr 20263
Strong Buy
9
Buy
2
Hold
1
Sell
0
Strong Sell
80.0%
Buy Rating
Price Chart
Similar Stocks
ASMB
Assembly Biosciences Inc
$537.9M
STTK
Shattuck Labs Inc
$231.0M
MYGN
Myriad Genetics Inc
$573.3M
RGNX
Regenxbio Inc
$729.0M
LXEO
Lexeo Therapeutics Inc
$724.8M
AURA
Aura Biosciences Inc
$346.1M
VNDA
Vanda Pharmaceuticals Inc
$521.2M
AVTX
Avalo Therapeutics Inc
$329.3M
STRO
Sutro Biopharma Inc
$98.6M
About Altimmune, Inc. - Common Stock
Компанія Altimmune, Inc. (ALT) – біотехнологічна компанія, що розробляє імунотерапевтичні препарати для лікування інфекційних захворювань та ожиріння. Altimmune займає нішу в розробці інноваційних пептидних кандидатів, маючи потенціал для створення більш ефективних та безпечних методів лікування, але знаходиться на ранній стадії розвитку, що робить її залежною від успішних клінічних випробувань.
Earnings
Beat rate: 75.0%
Next Report
May 11, 2026
EPS Estimate: $-0.25
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.25 | — | — |
| Dec 2025 | $-0.25 | $-0.27 | $-0.02 |
| Sep 2025 | $-0.28 | $-0.21 | +$0.07 |
| Jun 2025 | $-0.33 | $-0.27 | +$0.06 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $5K | $5K | $5K | $5K | $26K |
| Net Income | — | -$23.2M | -$19.6M | -$22.1M | -$19.0M | -$27.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -62.6% | -62.6% | -62.6% | -62.6% | -54.8% | -54.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -442920.0% | -438730.0% | -438730.0% | -438730.0% | -419575.0% | -419575.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 8.88 | 8.88 | 8.88 | 8.88 | 7.78 | 7.78 |
| Current Ratio | 20.44 | 20.44 | 20.44 | 20.44 | 17.18 | 17.18 |
Key Ratios
ROA (TTM)
-47.6%
P/S (TTM)
18833.80
P/B
4.2
EPS (TTM)
$-1.07
Rev Growth 3Y
-83.5%
52W High
$8.05
52W Low
$2.90
$2.90
52-Week Range
$8.05
Financial Health
Free Cash Flow
-$19.4M
Net Debt
-$8.1M
Cash
$43.8M
Total Debt
$35.7M
As of Dec 31, 2025
How does ALT compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ALT valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
18833.8
▲
146467%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
4.2
▲
69%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ALT profitability vs Biotechnology peers
ROE
-54.8%
▲
19%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-419575.0%
▼
146221%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-47.6%
▼
2%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
ALT financial health vs Biotechnology peers
D/E ratio
7.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
17.2
▲
287%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.0
▼
99%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ALT fundamentals radar
ALT
Peer median
Industry
ALT profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ALT vs peers: key metrics
Latest News
Everyone Warns That Out-Of-State Investing Is A Bad Idea. These Investors Say …
Yahoo Finance · Apr 05
Walt Disney Has Been a Streaming Story for Years. Here's How The …
Nasdaq · Apr 05
If You'd Invested $100 in CVS Health (CVS) Stock 5 Years Ago, …
Nasdaq · Apr 05
UnitedHealth Stock Analysis: Generational Buying Opportunity or a Falling Knife to Avoid?
Nasdaq · Apr 05
Less Than Half Of Health Care Workers Received An Updated COVID-19 Vaccine: …
ZeroHedge · Apr 05